1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Epigenetics
  3. Sirtuin

Sirtuin

Sirtuin (Sir2 proteins) are a class of proteins that possess either mono-ADP-ribosyltransferase, or deacylase activity, including deacetylase, desuccinylase, demalonylase, demyristoylase and depalmitoylase activity. Sirtuins regulate important biological pathways in bacteria, archaeaand eukaryotes. Sirtuins have been implicated in influencing a wide range of cellular processes like aging, transcription, apoptosis, inflammation and stress resistance, as well as energy efficiency and alertness during low-calorie situations. Sirtuins can also control circadian clocks and mitochondrial biogenesis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158162
    SIRT3 activator 1
    Activator 98.14%
    SIRT3 activator 1 (Compound 5v) is a SIRT3 activator. SIRT3 activator 1 selectively elevates SIRT3 expression, leading to the upregulation of SOD2 and OPA1 expression, effectively preventing mitochondrial dysfunction, mitigating oxidative stress, and preserving cardiomyocyte viability. SIRT3 activator 1 can be used for research of cardiovascular diseases.
    SIRT3 activator 1
  • HY-135644
    Rencofilstat
    Inhibitor
    Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease.
    Rencofilstat
  • HY-112427
    Sirt2-IN-1
    Inhibitor 98.71%
    Sirt2-IN-1 (Compound 9) is a sirtuin 2 (Sirt2) inhibitor with an IC50 of 163 nM.
    Sirt2-IN-1
  • HY-122936
    Tanshindiol C
    Activator 98.47%
    Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC50 of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research.
    Tanshindiol C
  • HY-151519
    SIRT2-IN-9
    Inhibitor 99.45%
    SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer.
    SIRT2-IN-9
  • HY-111522
    RK-9123016
    Inhibitor 99.02%
    RK-9123016 is a potent inhibitor of SIRT2. RK-9123016 inhibits the enzymatic activity of SIRT2 with an IC50 value of 0.18 µM but not other human sirtuin members including SIRT1 and SIRT3 at 100 µM. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression.
    RK-9123016
  • HY-15452B
    (R)-Selisistat
    98.03%
    (R)-Selisistat ((R)-EX-527) is a R-enantiomer of Selisistat. Selisistat (EX-527) is a potent and selective SIRT1 inhibitor with IC50 of 98 nM.
    (R)-Selisistat
  • HY-B0879
    Suramin
    Inhibitor
    Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor.Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
    Suramin
  • HY-148408
    SIRT2-IN-11
    Inhibitor 99.94%
    SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC50 value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers.
    SIRT2-IN-11
  • HY-168574
    SZU-B6
    Degrader 98.78%
    SZU-B6 is a PROTAC degrader for SIRT6 with DC50 of 45 nM and 154 nM in cell SK-HEP-1 and Huh-7. SZU-B6 inhibits the proliferation of cell SK-HEP-1 with an IC50 of 1.51 μM, inhibits the colony formation of SK-HEP-1 and Huh-7, induces apoptosis and arrests the cell cycle at G2/M phase in SK-HEP-1. SZU-B6 exhibits antitumor efficacy in mouse model. (Pink: ligand for target protein (HY-16605); Black: linker (HY-W012935); BLue: ligand for E3 ligase (HY-W453548)
    SZU-B6
  • HY-RS12943
    SIRT3 Human Pre-designed siRNA Set A
    Inhibitor

    SIRT3 Human Pre-designed siRNA Set A contains three designed siRNAs for SIRT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SIRT3 Human Pre-designed siRNA Set A
    SIRT3 Human Pre-designed siRNA Set A
  • HY-NP019
    Agkistrodon halys batroxobin
    Inhibitor
    Agkistrodon halys batroxobin is a thrombin-like serine protease. Agkistrodon halys batroxobin reduces the expression of Sirt1 and extracellular signal-regulated kinase activation in brain tissue. Agkistrodon halys batroxobin reduces cleaved caspase-3 expression and inhibits neuronal apoptosis in rat.
    Agkistrodon halys batroxobin
  • HY-159124
    YZL-51N
    Inhibitor
    YZL-51N is a selective SIRT7 inhibitor with IC50 value of 12.71 μM. YZL-51N disrupts SIRT7 enzyme activity by occupying the NAD+ binding pocket, thereby weakening DNA damage repair and inhibiting cancer cell survival. YZL-51N possesses anti-tumor activity and can be used in cancer research.
    YZL-51N
  • HY-RS12947
    SIRT5 Human Pre-designed siRNA Set A
    Inhibitor

    SIRT5 Human Pre-designed siRNA Set A contains three designed siRNAs for SIRT5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SIRT5 Human Pre-designed siRNA Set A
    SIRT5 Human Pre-designed siRNA Set A
  • HY-111329
    JGB1741
    Inhibitor 99.05%
    JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC50>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research.
    JGB1741
  • HY-W025074
    BML-278
    Activator 98.49%
    BML-278 is a SIRT1 activator (EC150: 1 μM). BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts.
    BML-278
  • HY-RS12950
    SIRT6 Human Pre-designed siRNA Set A
    Inhibitor

    SIRT6 Human Pre-designed siRNA Set A contains three designed siRNAs for SIRT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SIRT6 Human Pre-designed siRNA Set A
    SIRT6 Human Pre-designed siRNA Set A
  • HY-P5247A
    Palmitoyl tetrapeptide-20 TFA
    Activator
    Palmitoyl tetrapeptide-20 (PTP20) TFA is a biomimetic peptide agonist of α-MSH. Palmitoyl tetrapeptide-20 TFA promotes hair pigmentation and delays hair graying by activating the MC1-R pathway (AC50: 0.16 nM), enhancing catalase activity to reduce H2O2 accumulation, and upregulating SIRT1 activity. Palmitoyl tetrapeptide-20 TFA can be used in research on preventing hair loss and improving hair graying.
    Palmitoyl tetrapeptide-20 TFA
  • HY-156027
    SIRT6-IN-3
    Inhibitor 98.19%
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.
    SIRT6-IN-3
  • HY-118343
    AC-93253
    Inhibitor 99.3%
    AC-93253 is a selective, potent SIRT2 inhibitor. AC93253 can inhibit SIRT2 with an IC50 value of 6 μM. AC93253 can be used for the research of tumors.
    AC-93253
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.